Neurobiology of Disease (I.C.C.), Molecular Pharmacology and Experimental Therapeutics (A.O.B.), and Department of Immunology (C.R.-R., K.N.K., K.E.H.), Mayo Clinic College of Medicine, Mayo Graduate School, Mayo Clinic, Rochester, Minnesota.
Mol Pharmacol. 2014 Apr;85(4):542-52. doi: 10.1124/mol.113.089714. Epub 2014 Jan 22.
CXC chemokine receptor 4 (CXCR4) is a G protein-coupled receptor (GPCR) located on the cell surface that signals upon binding the chemokine stromal derived factor-1 (SDF-1; also called CXCL 12). CXCR4 promotes neuroblastoma proliferation and chemotaxis. CXCR4 expression negatively correlates with prognosis and drives neuroblastoma growth and metastasis in mouse models. All functions of CXCR4 require its expression on the cell surface, yet the molecular mechanisms that regulate CXCR4 cell-surface levels in neuroblastoma are poorly understood. We characterized CXCR4 cell-surface regulation in the related SH-SY5Y and SK-N-SH human neuroblastoma cell lines. SDF-1 treatment caused rapid down-modulation of CXCR4 in SH-SY5Y cells. Pharmacologic activation of protein kinase C similarly reduced CXCR4, but via a distinct mechanism. Analysis of CXCR4 mutants delineated two CXCR4 regions required for SDF-1 treatment to decrease cell-surface CXCR4 in neuroblastoma cells: the isoleucine-leucine motif at residues 328 and 329 and residues 343-352. In contrast, and unlike CXCR4 regulation in other cell types, serines 324, 325, 338, and 339 were not required. Arrestin proteins can bind and regulate GPCR cell-surface expression, often functioning together with kinases such as G protein-coupled receptor kinase 2 (GRK2). Using SK-N-SH cells which are naturally deficient in β-arrestin1, we showed that β-arrestin1 is required for the CXCR4 343-352 region to modulate CXCR4 cell-surface expression following treatment with SDF-1. Moreover, GRK2 overexpression enhanced CXCR4 internalization, via a mechanism requiring both β-arrestin1 expression and the 343-352 region. Together, these results characterize CXCR4 structural domains and β-arrestin1 as critical regulators of CXCR4 cell-surface expression in neuroblastoma. β-Arrestin1 levels may therefore influence the CXCR4-driven metastasis of neuroblastoma as well as prognosis.
CXC 趋化因子受体 4(CXCR4)是一种位于细胞表面的 G 蛋白偶联受体(GPCR),与趋化因子基质衍生因子-1(SDF-1;也称为 CXCL12)结合后会发出信号。CXCR4 促进神经母细胞瘤的增殖和趋化作用。CXCR4 的表达与预后呈负相关,并在小鼠模型中驱动神经母细胞瘤的生长和转移。CXCR4 的所有功能都需要其在细胞表面表达,然而,调节神经母细胞瘤中 CXCR4 细胞表面水平的分子机制还知之甚少。我们在相关的 SH-SY5Y 和 SK-N-SH 人神经母细胞瘤细胞系中对 CXCR4 的细胞表面调节进行了表征。SDF-1 处理导致 SH-SY5Y 细胞中 CXCR4 的快速下调。蛋白激酶 C 的药理学激活也降低了 CXCR4,但通过一种不同的机制。对 CXCR4 突变体的分析描绘了两个 CXCR4 区域,这些区域对于 SDF-1 处理来减少神经母细胞瘤细胞表面的 CXCR4 是必需的:残基 328 和 329 处的异亮氨酸-亮氨酸基序和残基 343-352。相比之下,与其他细胞类型中 CXCR4 的调节不同,丝氨酸 324、325、338 和 339 不是必需的。 arrestin 蛋白可以结合并调节 GPCR 细胞表面表达,通常与 G 蛋白偶联受体激酶 2(GRK2)等激酶一起发挥作用。使用天然缺乏β-arrestin1 的 SK-N-SH 细胞,我们表明β-arrestin1 是调节 SDF-1 处理后 CXCR4 细胞表面表达所必需的,这是通过 343-352 区域实现的。此外,GRK2 的过表达通过一种需要β-arrestin1 表达和 343-352 区域的机制增强了 CXCR4 的内化。总之,这些结果将 CXCR4 结构域和β-arrestin1 描绘为神经母细胞瘤中 CXCR4 细胞表面表达的关键调节剂。β-arrestin1 的水平因此可能会影响神经母细胞瘤的 CXCR4 驱动转移以及预后。